22 completed, 2 withdrawn, 1 recruiting, 1 terminated. 10 Phase 4, 7 Phase 3, 3 Not applicable, 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 8, Withdrawn 2 |
| Phase 3 | 7 | Completed 6, Terminated 1 |
| Not applicable | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Vytorin: new trials by email Literature Review of Vytorin trials Research Report on Vytorin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer Vytorin, Ezetimibe - Prostate Cancer | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 140 | 2024-07-16 | 2026-03-11 |
| Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal ezetimibe 10mg-simvastatin 40mg - Prostate Cancer | Early Phase 1 | Completed | Cedars-Sinai Medical Center | 63 | 2015-09-01 | 2023-02-22 |
| Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation., Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation. - Hypercholesterolemia, Dyslipidemia | Phase 3 | Completed | Ache Laboratorios Farmaceuticos S.A. | 129 | 2013-03-01 | 2020-01-22 |
| A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406) Ezetimibe/simvastatin, Other Statin - Dyslipidemia | Phase 4 | Withdrawn | Organon and Co | 2013-03-01 | 2022-02-18 | |
| Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy calcined magnesia, Ezetimibe/simvastatin, Rosuvastatin - Oxidative Stress, Diabetic Polyneuropathy | Phase 2 | Completed | University of Guadalajara | 74 | 2012-02-01 | 2014-05-06 |
| Vascular and Metabolic Effects of Vytorin vs Simvastatin placebo, vytorin, simvastatin - Hypercholesterolemia | Phase 4 | Completed | Gachon University Gil Medical Center | 204 | 2011-11-01 | 2014-11-04 |
| Vascular and Metabolic Effects of Vytorin placebo, vytorin - Hypercholesterolemia | Phase 4 | Completed | Gachon University Gil Medical Center | 204 | 2011-07-01 | 2014-11-04 |
| Vytorin in the Treatment of Alopecia Areata vytorin - Alopecia Areata | Phase 1 | Completed | University of Miami | 29 | 2011-07-01 | 2015-03-17 |
| To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects Vytorin, Placebo - Inflammation | Not applicable | Completed | University at Buffalo | 20 | 2011-05-01 | 2024-04-17 |
| Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors ezetimibe/simvastatin 10/20 mg + placebo, ezetimibe/simvastatin 10/20 mg + MK0524A - Cardiovascular Diseases, Hyperlipidemia | Phase 4 | Withdrawn | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 2009-11-01 | 2015-03-24 | |
| Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction Simvastatin, Ezetimibe-Simvastatin - Myocardial Infarction | Phase 4 | Completed | Brasilia Heart Study Group | 40 | 2009-05-01 | 2010-03-24 |
| Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED) ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin - Cardiovascular Disorder, Diabetes Mellitus | Phase 3 | Completed | Organon and Co | 808 | 2009-04-01 | 2024-05-16 |
| Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment simvastatin, ezetimibe/simvastatin - Metabolic Syndrome | Phase 4 | Completed | University of Maryland, Baltimore | 15 | 2009-01-01 | 2020-01-14 |
| Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED) ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg - Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 250 | 2008-11-01 | 2024-05-16 |
| Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168) valsartan, pravastatin, simvastatin - Hypertension | Phase 3 | Terminated | Fundación Lindavista del Corazón AC | 12 | 2008-01-01 | 2013-08-26 |
| Vascular Effects of Ezetimibe/Simvastatin and Simvastatin on Atherosclerosis Simvastatin (Zocor), 10mg/10mg of Ezetimibe/Simvastatin (Vytorin) - Atherosclerosis | Phase 4 | Completed | National Cheng-Kung University Hospital | 40 | 2007-09-01 | 2010-02-24 |
| Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2) Vytorin + Niaspan, Vytorin, Niaspan - Hypercholesterolemia, Hyperlipidemia | Phase 1 | Completed | Organon and Co | 18 | 2007-05-01 | 2022-02-16 |
| Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes Simvastatin, Ezetimibe/Simvastatin - Type 1 Diabetes Mellitus, Dyslipidemia | Phase 2 | Completed | University of Colorado, Denver | 9 | 2007-05-01 | 2020-11-10 |
| Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol Vytorin, Simvastatin - Hypercholesterolemia | Phase 4 | Completed | Bronx VA Medical Center | 34 | 2007-03-01 | 2013-07-03 |
| Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Simvastatin, Vytorin, Placebo - Metabolic Syndrome | Phase 4 | Completed | Baylor College of Medicine | 30 | 2007-03-01 | 2023-11-30 |
Showing 20 of 26. Sign in to see all of them.
Hypercholesterolemia (8) · Cardiovascular Diseases (4) · Atherosclerosis (3) · Dyslipidemias (3) · Angina Pectoris (2) · Diabetes Mellitus (2) · Hyperlipidemias (2) · Hypertension (2) · Inflammation (2) · Insulin Resistance (2) · Metabolic Syndrome (2) · Myocardial Infarction (2) · Peripheral Arterial Disease (2) · Prostatic Neoplasms (2) · Acute Coronary Syndrome (1)
Organon and Co (6) · Cedars-Sinai Medical Center (2) · Gachon University Gil Medical Center (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Baylor College of Medicine (1) · Brasilia Heart Study Group (1) · Bronx VA Medical Center (1) · Fundación Lindavista del Corazón AC (1) · Hospital Universitario 12 de Octubre (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · National Cheng-Kung University Hospital (1) · University at Buffalo (1) · University of Colorado, Denver (1) · University of Guadalajara (1) · University of Maryland, Baltimore (1)
United States (9) · Brazil (3) · South Korea (2) · Mexico (1) · Taiwan (1) · United Kingdom (1)
Adolfo D Rodriguez-Carrizalez, PhD, MD (1) · Alejandra G Miranda-Diaz, PhD,MD,FACS (1) · Alejandra Meaney, MD, PhD (1) · Andrei C Sposito, MD, PhD (1) · Christie Ballantyne, M.D. (1) · Christopher M Kramer, M.D. (1) · Chu-Huang Chen, M.D., Ph.D. (1) · Colin Baigent (1) · David M Maahs, MD (1) · Francisco Fonseca, physician (1) · Geannyne Villegas-Rivera, PhD, MD (1) · Hyung Kim, MD (1) · Hyung L Kim, MD (1)
PMID 18376000, PMID 18376001, PMID 18765432, PMID 19061694, PMID 19075102, PMID 19660694, PMID 20599002, PMID 21120461, PMID 21570685, PMID 21867844, PMID 22293030, PMID 23018312, PMID 23279632, PMID 23288881, PMID 23739650, PMID 23866306, PMID 25014686, PMID 26290682, PMID 26330412, PMID 26486166, PMID 26821621, PMID 27407053, PMID 28231942, PMID 28291866, PMID 28506979, PMID 28711708, PMID 28972004, PMID 29151034, PMID 29263150, PMID 29449329, PMID 29903515, PMID 30396865, PMID 30630361, PMID 30739657, PMID 30821829, PMID 31314050, PMID 31447131, PMID 31805983, PMID 32081289, PMID 32904162, PMID 34396246, PMID 34620406, PMID 35112882, PMID 36260325, PMID 38018702, PMID 41271821
K23DK075360 (1), R01CA280060 (1), R01HL075792 (1)